Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma

PURPOSE: Characterize bortezomib pharmacokinetics/pharmacodynamics in relapsed myeloma patients after single and repeat intravenous administration at two doses. METHODS: Forty-two patients were randomized to receive bortezomib 1.0 or 1.3 mg/m(2), days 1, 4, 8, 11, for up to eight 21-day treatment cy...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Reece, Donna E., Sullivan, Dan, Lonial, Sagar, Mohrbacher, Ann F., Chatta, Gurkamal, Shustik, Chaim, Burris, Howard, Venkatakrishnan, Karthik, Neuwirth, Rachel, Riordan, William J., Karol, Michael, von Moltke, Lisa L., Acharya, Milin, Zannikos, Peter, Stewart, A. Keith
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2010
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3951913/
https://ncbi.nlm.nih.gov/pubmed/20306195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-010-1283-3
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg